Skip to main content

Revvity, Inc. (RVTY) Stock Analysis

SellVALUE-TRAP 1/5Moderate Confidence

Healthcare · Diagnostics & Research

Earnings in 5 days (2026-05-05). Expect elevated volatility around the report — consider waiting for post-earnings price action before new entries.

Sell if holding. Momentum 1.3/10 is below the 5.0 floor at $85.74 — engine's falling-knife protection flags exit rather than catching a breakdown. Specifics: Concentration risk — Supplier: limited or single sources of supply; Earnings in 5 days (event risk).

Revvity provides health science tools across Life Sciences and Diagnostics segments, serving pharmaceutical, biotech, academic, and government customers in 160+ countries with approximately 11,000 employees. Revenue is generated through instruments, reagents, software, and... Read more

$85.74+15.5% A.UpsideScore 4.9/10#19 of 25 Diagnostics & Research
Stop $79.83Target $99.12(analyst − 13%)A.R:R 1.8:1
Analyst target$113.93+32.9%14 analysts
$99.12our TP
$85.74price
$113.93mean
$140

Sell if holding. Momentum 1.3/10 is below the 5.0 floor at $85.74 — engine's falling-knife protection flags exit rather than catching a breakdown. Specifics: Concentration risk — Supplier: limited or single sources of supply; Earnings in 5 days (event risk). Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Score 4.9/10, moderate confidence.

Passes 5/8 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, semi cycle peak clear). Fails on weak momentum and death cross (50MA < 200MA) and earnings proximity 5d<=7d. Suitability: moderate.

Thesis

Rewards
Strong earnings beat streak (3/4)
Attractive valuation
Risks
Concentration risk — Supplier: limited or single sources of supply
Earnings in 5 days (event risk)
Weak overall score: 4.9/10

Key Metrics

P/E (TTM)39.9
P/E (Fwd)13.7
Mkt Cap$9.2B
EV/EBITDA13.9
Profit Mgn8.4%
ROE3.2%
Rev Growth5.9%
Beta1.13
Dividend0.34%
Rating analysts26

Quality Signals

Piotroski F9/9

Options Flow

P/C0.12bullish
IV77%elevated
Max Pain$60-30.0% vs spot

Concentration Risks(10-K Item 1A)

  • HIGHSupplierlimited or single sources of supply
    10-K Item 1A: 'certain critical raw materials, key components and other goods ... are available from limited or single sources of supply'

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer

Rating Breakdown

2 floor-breakers

Price action weak — below key moving averages, no momentum carry. Needs a base before trend-continuation setups apply.static

Macd
0.0
Volume
0.0
Obv
1.0
Ma Position
1.0
Rsi
4.5
Volume distribution (falling OBV)Below 200-MA, MA slope -1.2%/30d — confirmed downtrend

Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static

Growth Rank
2.8
Value Rank
4.0
Quality Rank
4.2
GatesMomentum 1.3<4.5Death cross (50MA < 200MA)EARNINGS PROXIMITY 5d<=7dA.R:R 1.8 ≥ 1.5Insider activity: OKNo SEC red flagsNEWS EVENTS NONE RECENTSEMI CYCLE PEAK CLEARSuitability: Moderate
RSI
44 · Neutral
20D MA 50D MA 200D MADEATH CROSSSupport $81.22Resistance $97.07

Price Targets

$80
$99
A.Upside+15.6%
A.R:R1.8:1

Position Sizing

ConvictionNone
Suggested %0.5%
Max %1%
RegimeCautious

Risk Alerts

! Momentum score 1.3/10 — below 4.5 minimum
! Death cross — 50-day MA below 200-day MA
! EARNINGS_PROXIMITY:5d<=7d

Earnings

B
B
B
M
3/4 beats
Next Earnings2026-05-05 (5d)

Verdict History

reverse chrono — latest first
Loading history...
Verdicts are recorded on every nightly pipeline run. Rows capture transitions (verdict flips, score deltas ≥0.3, entry/TP/SL changes). Rows with a ▶ can be expanded to see the change reason. Aggregate cohort performance is tracked in the recommendation ledger.
Frequently Asked Questions
Is RVTY stock a buy right now?

Sell if holding. Momentum 1.3/10 is below the 5.0 floor at $85.74 — engine's falling-knife protection flags exit rather than catching a breakdown. Specifics: Concentration risk — Supplier: limited or single sources of supply; Earnings in 5 days (event risk). Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Prior stop was $79.83. Score 4.9/10, moderate confidence.

What is the RVTY stock price target?

Take-profit target: $99.12 (+15.5% upside). Prior stop was $79.83. Stop-loss: $79.83.

What are the risks of investing in RVTY?

Concentration risk — Supplier: limited or single sources of supply; Earnings in 5 days (event risk); Weak overall score: 4.9/10.

Is RVTY overvalued or undervalued?

Revvity, Inc. trades at a P/E of 39.9 (forward 13.7). TrendMatrix value score: 7.1/10. Verdict: Sell.

What do analysts say about RVTY?

26 analysts cover RVTY with a consensus score of 3.8/5. Average price target: $114.

What does Revvity, Inc. do?Revvity provides health science tools across Life Sciences and Diagnostics segments, serving pharmaceutical, biotech,...

Revvity provides health science tools across Life Sciences and Diagnostics segments, serving pharmaceutical, biotech, academic, and government customers in 160+ countries with approximately 11,000 employees. Revenue is generated through instruments, reagents, software, and services across drug discovery, diagnostics, and screening workflows.

Related stocks: WGS (GeneDx Holdings Corp.) · NEO (NeoGenomics, Inc.) · SHC (Sotera Health Company) · GH (Guardant Health, Inc.) · IQV (IQVIA Holdings, Inc.)